bims-imsemeImmunosenescence and T cell metabolism
This report is maintained by Pierpaolo Ginefra, Ludwig Institute for Cancer Research. It brings out roughly 18 papers per issue.
0000‒00‒00
 Sign up
2026–05–03
2026–04–26
0000‒00‒00
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
2026–04–19
2026–04–12
2026–04–05
2026–03–29
2026–03–22
2026–03–15
2026–03–08
2026–03–01
2026–02–22
2026–02–15
2026–02–08
2026–02–01
2026–01–25
2026–01–18
2026–01–11
2026–01–04
2025–12–28
2025–12–21
2025–12–14
2025–12–07
2025–11–30
2025–11–23
2025–11–16
2025–11–09
2025–11–02
2025–10–26
2025–10–19
2025–10–12
2025–10–05
2025–09–28
2025–09–21
2025–09–14
2025–09–07
2025–08–31
2025–08–24
2025–08–17
2025–08–10
2025–08–03
2025–07–27
2025–07–20
2025–07–13
2025–07–06
2025–06–29
2025–06–22
2025–06–15
2025–06–08
2025–06–01
2025–05–25
2025–05–18
2025–05–11
2025–05–04
2025–04–27
2025–04–20
2025–04–13
2025–04–06
2025–03–30
2025–03–23
2025–03–16
2025–03–09
2025–03–02
2025–02–23
2025–02–16
2025–02–09
2025–02–02
2025–01–26
2025–01–19
2025–01–12
2025–01–05
2024–12–29
2024–12–22
2024–12–15
2024–12–08
2024–12–01
2024–11–24
2024–11–17
2024–11–10
2024–11–03
2024–10–27
2024–10–20
2024–10–13
2024–10–06
2024–09–29
2024–09–22
2024–09–15
2024–09–08
2024–09–01
2024–08–25
2024–08–18
2024–08–11
2024–08–04
2024–07–28
2024–07–21
2024–07–14
2024–07–07
2024–06–30
2024–06–23
2024–06–16
2024–06–09
2024–06–02
2024–05–26
2024–05–19
2024–05–12
2024–05–05
2024–04–28
2024–04–21
2024–04–14
2024–04–07
2024–03–31
2024–03–24
2024–03–17
2024–03–10
2024–03–03
2024–02–25
2024–02–18
2024–02–11
2024–02–04
2024–01–28
2024–01–21
2024–01–14
2024–01–07
2023–12–31
2023–12–24
2023–12–17
2023–12–10
2023–12–03
2023–11–26
2023–11–19
2023–11–12
2023–11–05
2023–10–29
2023–10–22
2023–10–15
2023–10–08
2023–10–01
2023–09–24
2023–09–17
2023–09–10
2023–09–03
2023–08–27
2023–08–20
2023–08–13
2023–08–06
2023–07–30
2023–07–23
2023–07–16
2023–07–09
2023–07–02
2023–06–25
2023–06–18
2023–06–11
2023–06–04
2023–05–28
2023–05–21
2023–05–14
2023–05–07
2023–04–30
2023–04–23
2023–04–16
2023–04–09
2023–04–02
2023–03–26
2023–03–19
2023–03–12
2023–03–05
2023–02–26
2023–02–19
2023–02–12
2023–02–05
2023–01–29
2023–01–22
2023–01–15
2023–01–08
2023–01–01
2022–12–25
2022–12–18
2022–12–11
2022–12–04
2022–11–27
2022–11–20
2022–11–13
2022–11–06
2022–10–30
2022–10–23
2022–10–16
2022–10–09
2022–10–02
2022–09–25
2022–09–18
2022–09–11
2022–09–04
2022–08–28
2022–08–21
2022–08–14
2022–08–07
2022–07–31
2022–07–24
2022–07–17
2022–07–10
2022–07–03
2022–06–26
2022–06–19
2022–06–12
2022–06–05
2022–05–29
2022–05–22
2022–05–15
2022–05–08
2022–05–01
2022–04–24
2022–04–17
2022–04–10
2022–04–03
2022–03–27
2022–03–20
2022–03–13
2022–03–06
2022–02–27
2022–02–20
2022–02–13
2022–02–06
2022–01–30
2022–01–23
2022–01–16
2022–01–09
2022–01–02
2021–12–26
2021–12–19
2021–12–12
2021–12–05
2021–11–28
2021–11–21
2021–11–14
2021–11–07
2021–10–31
2021–10–24
2021–10–17
2021–10–10
2021–10–03
2021–09–26
2021–09–19
2021–09–12
2021–09–05
2021–08–29
2021–08–22
2021–08–15
2021–08–08
2021–08–01
2021–07–25
2021–07–18
2021–07–11
2021–07–04
2021–06–27
2021–06–20
2021–06–13
2021–06–06
2021–05–30
2021–05–23
2021–05–16
2021–05–09
2021–05–02
2021–04–25
2021–04–18
2021–04–11
2021–04–04
2021–03–28
2021–03–21
2021–03–14
2021–03–07
2021–02–28
2021–02–21
2021–02–14
2021–02–07
2021–01–31
2021–01–24
2021–01–17
2021–01–10
2021–01–03
2020–12–27
2020–12–20
2020–12–13
2020–12–06
2020–11–29
2020–11–22
2020–11–15
2020–11–08
2020–11–01
2020–10–25
2020–10–18
2020–10–11
2020–10–04
2020–09–27
2020–09–20
2020–09–13
2020–09–06
2020–08–30
2020–08–23
2020–08–16
2020–08–09
2020–08–02
2020–07–26
2020–07–19
2020–07–12
Pierpaolo Ginefra also maintains a report bims-tuinly on “Tumor-infiltrating lymphocytes therapy” .
Here are the seven most related reports.
 1. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-imicid“Immunometabolism of infection, cancer and immune-mediated disease”, ∼ 30 p.p.i. ∼ 30 papers per issue
 2. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-camemi“Mitochondrial metabolism in cancer”, ∼ 47 p.p.i. ∼ 47 papers per issue
 3. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-tuinly“Tumor-infiltrating lymphocytes therapy”, ∼ 18 p.p.i. ∼ 18 papers per issue
 4. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-mithem“Mitochondria in Hematopoiesis”, ∼ 5 p.p.i. ∼ 5 papers per issue
 5. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-mibica“Mitochondrial bioenergetics in cancer”, ∼ 25 p.p.i. ∼ 25 papers per issue
 6. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-cagime“Cancer, aging and metabolism”, ∼ 35 p.p.i. ∼ 35 papers per issue
 7. 
0000‒00‒00
 Signing up
0000‒00‒00
 Signed up
bims-nimamd“Neuroimmunity and neuroinflammation in ageing and metabolic disease”, ∼ 37 p.p.i. ∼ 37 papers per issue
This page is being maintained by Thomas Krichel. It was last updated on 2026‒05‒03 at 6:58.